Introduction
Human tumor cell lines may be used: (1) to model specific types of normal or neoplastic cell; (2) to study differentiation; (3) as aids to pathology and diagnosis; and (4) as self-renewing resources of oncogenically modified macromolecules, eg as required in novel antitumor therapies. In all cases, the availability of authentic, well-characterized cell lines is usually taken for granted and the identity of cell stocks rarely checked. Bogus cell lines may unwittingly arise from primary cultures suffering cross-contamination by established cell lines; and for established cell lines procured indirectly via third parties this risk is compounded accordingly. Acknowledging the extent of the problem, some (but not all) cell repositories consider it necessary to verify the identity of (authenticate) cell lines prior to their distribution to other investigators using a variety of methods, principally by combining cytogenetics with DNA fingerprinting. 1 Among tumors represented by only a limited number of in vitro models one or a few may come to predominate, eg the Dami megakaryocyte 2 and HEL erythroleukemia (EL) cell lines. 3 The outstanding features of some favored cell lines, eg responses to differentiating agents, may even come to be extrapolated to primary tumors or normal tissue, particularly when scarce or difficult to isolate. While the importance of basing such inferences on authenticated and well characterized cell lines is apparent, this stricture is unevenly enforced by journal editors and reviewers.
Only a limited number of in vitro models of human megakaryocytopoiesis are widely available. The most often cited of these is Dami (62 citations between 1989 and 1997). Here we present the results of karyotyping and DNA fingerprinting studies, which together show it to have been contaminated by HEL during establishment, ie prior to its widespread distribution to other investigators. As well as showing that the origin of Dami renders it inappropriate to model the general behavior of normal or neoplastic cells of the megakaryocyte lineage, our results underline the need to submit candidate tumor cell lines to effective authentication and characterization procedures which we recommend to include cytogenetics combined with DNA fingerprinting.
Materials and methods

Cell lines
Dami was established from a patient with acute megakaryocytic leukemia (AMegL) in December 1986. Stocks of Dami were originally deposited at the ATCC by Dr SM Greenberg, Brigham and Women's Hospital, Boston, MA, USA. Samples prepared directly from original material are hereafter referred to as 'donor stock'; while later passage material derived from this is termed 'distribution stock'. Unfortunately initial founding-passage stocks of Dami are no longer available from the originators for direct comparison, having been lost following a freezer accident (R Handin, personal communication to RJH).
The (detailed and accurate) descriptive karyotype originally published for Dami, performed at or around July 1987, 8 months after establishment, 2 transcribed according to current (ISCN 1995) nomenclature 4 to facilitate comparison with our data was: 54-64Ͻ3nϾ, XY,−Y, add(1)(p21), t(1;6)(p13;p21), t(2;10)(10;?)(q21;p14;)(q23;?), add(3)(q26), t(3;6)(p13;q16), del(4)(q25), t(4;8)(q12;p11), t(5;17)(q11;p11), del(6)(q21), −7, add(8)(p11),−9,t(9;?)(?;11)(p24;?)(?;p15),t(9;?)(?;22)(p24;?) (?;p15),−10,t(?;11;21)(?;q11;q22),−14, add (15) 
DNA fingerprinting
Multilocus fingerprinting was carried out using 10 g of genomic DNA from distribution stocks of the following; HEL, DAMI (DSMZ), DAMI (ATCC) and HELA (control) cell lines, each digested with Hinfl and size-separated electrophoretically in a 1% agarose gel. For Southern analysis, alkaline blotting on to nylon membranes was performed, followed by hybridization with a digoxigenin-labeled oligonucleotide (gtg) 5 probe. Chemoluminescent detection was carried out according to the manufacturer's protocol (Boehringer Mannheim, Mannheim, Germany).
Analysis of restriction fragment length polymorphism was carried out using a polymerase chain reaction (PCR) assay as described previously. [5] [6] [7] Briefly, 100 ng human genomic high molecular weight DNA in 50 l total volume was overlayed with two drops of oil. The PCR reaction comprised the following: 20 pmol each of reverse and forward primer, 500 nmol dNTP, 5 l (10×) Taq polymerase buffer, 3 l MgCl 2 (15 mM), 0.6 units Taq polymerase. The cycle prolife is given below: The reaction products were extracted with an equal volume of chloroform and 5 l of each parallel PCR reaction product were mixed, run on a 5% polyacrylamide gel and silverstained after electrophoresis. The primer sequences used were:
ApoB forward: 5′ATGGAAACGGAGAAATTATG3′ ApoB reverse: 5′CCTTCTCACTTGGCAAATAC3′ dis80 forward: 5′GAAACTGGCCTCCAAACACTGCCCGCCG3′ D1S80 reverse: 5′GTCTTGTTGGAGATGCACGTGCCCCTTGC3′ D17S30 forward: 5′AAACTGCAGAGAGAAAGGTCGAAGAGTGAAGTG3′ D17S30 reverse: 5′AAAGGATCCCCCACATCCGCTCCCCAAGTT3′
Cytogenetic analysis
Standard cytogenetic harvesting, preparation and staining procedures were used throughout. Briefly, mitotic cells were harvested by colcemid arrest (0.004 M for 1.5 h) and, after hypotonic treatment with 0.075 M KCl and 0.9% NaCitrate (1:1 for 5 min), fixed in chilled methanol:acetic acid (3:1). Trypsin Gbanding and fluorescence in situ hybridization (FISH) were performed on slides after aging for 10 days. For G-banding, slides were incubated briefly (10-15 s) in trypsin solution and stained for 15 min in 5% Giemsa in Soerensen's buffer (pH 6.8). Analysis was performed using an Axioplan microscope (Carl Zeiss, Oberkoechen, Germany) configured to an image analysis system (Cytoscan 3; Applied Imaging, Warrington, UK) equipped with a high-resolution laser printer (Lasertechnics, Tuscon, AZ, USA). Consensus karyotypes were obtained by full analysis of 25 or more metaphases. FISH was performed using chromosome painting probes obtained from Cambio (Cambridge, UK) or Gibco-BRL (Paisley, UK). Hybridization and detection followed manufacturers' protocols. Slides were counterstained with 4,6-diamidino-2-phenylindole (DAPI; Sigma, Deisenhofen, Germany); mounted in a commercial antifade solution (Vectashield; Vector Laboratories, Burlingame, USA) and examined microscopically by epifluorescence illumination. Photographic images were recorded on Kodak Ektachrome 400 daylight reversal film. Karyotyopes were described according to ISCN 1995. 7 
Results
DNA fingerprinting
Identity of various stocks of HEL and Dami (including original ampoules of the donor stock of Dami submitted to the ATCC in August 1988) was confirmed by DNA profiling: Dami yields fingerprints identical to HEL after hybridization with either multi-locus (gtg) 5 
Karyotyping
The DSMZ distribution stock of HEL has the following karyotype: 60-64Ͻ3nϾXYY,−2, del(2)(q32), t(3;6)(p13;q16), der(5)t(5;17)(q10,q10),der(6)t(1;6)(p13;p21), der(7)add(7) (p14q;32),add(8)(p21),−9, der(9)t(9;?)(?;11)(p24;?)(?;q13); −10, −10, del(11)(q13), add (15) We found that late passage Dami has the following consensus karyotype: 59-64Ͻ3nϾXY/XYY, del(1)(p21p31), −2, del(2)(q32),add(3)(q26-28),del(4)(q24), der(5)t(5;17) (q10;q10), del(6)(q22), der(6)t(1;6)(p13;p21), der(6) t(3;6)(p13;q16), der(7)add(7)(p14;?q32), −9, add(8)(p21), der(9) t(9:?)(?;11)(p24;?)(?;q13), −10, −10, del(11)(q13), −14, i(14)(q10), add (15) 
Chromosome marker representation
Representation of the 18 structurally rearranged chromosomes (markers) defined in the original publication describing Dami 2 in distribution stocks of both Dami and HEL is shown in Table 1 and depicted in Figure 2 . To facilitate comparison with our data, the now-defunct nomenclature adopted in original report (column 1) has been updated to ISCN 1995 (column 2): while attempting to preserve their descriptive content in full, the few typographical errors and inconsistencies (concerning the use of parentheses) have been silently corrected. In the original report, structurally rearranged pairs of translocation products were not distinguished by the use of (der) and this convention has been followed, as questions of identity were unaffected. In confirming the presence of a particular rearrangement in current Dami or HEL (columns 3 and 4, respectively) a margin of error of plus or minus one chromosome band as recognized elsewhere 8 was deemed accept- (2)(q13). Where an original karyotypic term was indefinite, eg add(18)(p11), its pictorial representation was checked before deciding it to be the same we interpreted as t(18;21)(q10;q10), as revised with the benefit of FISH -a technique unavailable at the time of Dami's original karyotypic analysis, of course. Similarly, reference to the published image shows that t(2;10)(10;?)(q21;p14;q23;??) in Ref. 2 is the same rearrangement we have chosen to interpret as del(2)(q33) and der(7)add(7)(p14q32) -the only case of radical reinterpretation found necessary. Although one marker described in the original report, t(4;8)(q12;p11), may have been included among the two underfined markers currently present in both Dami and HEL, it was treated as absent. Only one original Dami marker, add(19)(p11), was clearly missing from current passages of Dami or HEL.
Distribution stocks of Dami have retained 16/18 markers originally described. Current passages of HEL at the DSMZ carry 10/18 of these markers (see Table 1 ) and themselves share only 12/20 markers, including the two undefined markers, despite yielding identical DNA fingerprints. To put this result in perspective, no other cell line in the DSMZ database of 237 human tumor cell line karyotypes carries more than two of these 18 markers. 9 In view of the overwhelming degree of cytogenetic similarity, it was concluded that current stocks of Dami at the DSMZ are effectively identical to the original stock described in Ref 2. The four columns list respectively: (1) all 18 structural rearrangements present in Dami at early passage verbatum as described in (2); (2) 
Origin of Dami
Dami's more recent dates of establishment (1986) and publication (1988) compared to HEL (both 1980) might appear sufficient to establish the latter's precedence and hence the direction of the contamination under review. Dami's founder has questioned the time and place but not the direction of contamination (R Handin, personal communication to R.J.H.). Although HEL was not described cytogenetically in any detail at the time of establishment, its original description in Ref.
3 is consistent with current karyotypes of both HEL and Dami cell lines. (Among the 390 papers citing HEL (Medline 1983-July 1997), we have been unable to retrieve any which report its karyotype.) The retention of normal homologues of chromosomes 6, 18 and 21 in HEL, but not in Dami, in which all homologues for these chromosomes are rearranged (Figure 2) , is further evidence of HEL's priority to Dami.
Discussion
We have shown that current, late passage stocks of Dami and HEL held at the DSMZ exhibit identical multilocus DNA fingerprints ( Figure 1a ) and a similar result was obtained for token-freeze stocks of Dami submitted to the ATCC in 1988 (Figure 1b) , the earliest passages now available. The accidental loss of earlier passages of Dami stored in its founding laboratory, frustrating direct investigation of their true identity by DNA fingerprinting analysis, led us to approach the latter question by cytogenetic means, given the presence in the original report of a detailed written and pictorial karyotype. Of 18 structures chromosome rearrangements described in the original report, the presence of 16 was confirmed in current distribution stocks of Dami, compared to only 12/20 shared by current stocks of Dami and HEL, the identity of which was established independently by DNA fingerprinting (Figure 1) . To put the strength of this degree of cytogenetic similarity in perspective, the presence of four or more shared markers identifying suspect contaminated cell lines at the DSMZ has been so far invariably (36/36 cases) confirmed by DNA fingerprinting (RAF MacLeod and WG Dirks, unpublished observations). These data support the scenario that Dami had been already heavily contaminated by HEL by the time of its cytogenetic characterization -performed within 8 months of establishment 2 -and well before its deposition with the ATCC or widespread distribution to other investigators. We propose that future reports of studies involving Dami should make explicit its derivation from HEL, and amend accordingly its classification to that of EL. The likelihood that most, if not all, of the 60+ reports presenting the results of experiments performed with Dami, instead used HEL, may require the results of some to be reappraised -in particular, those reaching generalizations about megakaryocyte behavior drawn from experiments with Dami alone, and those postulating homologies between megakaryocytopoiesis and erythropoiesis based on characteristics shared by the two cell lines. Table 2 Table.) clonal differences or mere 'experimental noise', may be worthy of further investigation. (None reported using Dami sourced prior to the time of its contamination.)
On the positive side, retention of at least 16/18 markers through extended passage by Dami, implies an unexpected degree of stability given its karyotypic complexity. This, together with the lesser degree of identity between current passages of Dami and HEL (12/20 markers), suggests that both cell lines may represent distinct subclones already present in earlier passages of HEL. A similar model explains the behavior of other tumor cell lines: the various sublines of Hela, despite their early isolation and extended opportunities for further evolution, are still instantly recognizable karyotypically -each having retained 6-7/10 standard Hela markers. 9 Thus, karyotypic instability -a charge often imputed to continuous cell lines -may in some instances apply to their founding passages only and may even represent actual neoplastic heterogeneity arising within the original tumor. HEL and its Dami subclone belong to the minority of hematopoietic cell lines which grow readily from clonal seeding densities, 3 exposed to a heightened risk of genetic drift due to 'bottlenecking'. Thus, Dami paired with HEL may display virtue in modelling tumor evolution -suggesting a possible explanation for 3/24 discordant studies (Table 2) .
That the contamination of one widely used and distributed cell line by another should go unrecognized for so long implies that the problem of misidentified or cross-contaminated cell lines may be more extensive than generally appreciated. Recent advances in cell authentication, in particular by combining cytogenetics with forensic DNA fingerprinting techniques, show that some 16% recently established human tumor cell lines have been misidentified or cross-contaminated by their parent laboratories alone (RAF MacLeod et al, manuscript in preparation). Without such an approach, combining the scope of cytogenetics (to shortlist suspect cell lines) with the precision of DNA fingerprinting (to convict or clear these suspects and also to pick up chronic 'culprits', eg Hela) the present instance might well have continued to escape detection. However, to expect of all users the routine and uniform application of both these methods -voracious of time and resources -might well appear unrealistic at present. In any case, only those with comprehensive holdings might be expected to carry data on sufficient potential contaminants to render the exercise worthwhile. Thus, the task of authenticating cell lines is at present best undertaken by those general cell repositories equipped and motivated to undertake it. 1 
